PAVmed Inc. (PAVM) Form 424B5 — Sep 9, 2026

$PAVMForm 424B5Filed Sep 9, 2026, 7:00 PM ET0001493152-26-042020Original filing

PAVmed filed a 424B5 prospectus supplement establishing a new at-the-market offering of up to $9.4 million of common stock through A.G.P./Alliance Global Partners as sales agent, with a fixed 3.0% commission and proceeds earmarked for working capital and general corporate purposes. There is no minimum offering amount. The new facility replaces the company's prior Maxim Group ATM, which was fully utilized and terminated after PAVmed sold 675,679 shares between July 1 and August 13, 2026 for net proceeds of approximately $2.8 million.

Key figures

Gross Proceeds: up to $9,400,000
Offering Price: $5.09 assumed for illustrative purposes (last reported sale $4.72 on Sept 8, 2026)
Shares Offered: approximately 1,846,758 shares assumed at $5.09/share (actual varies; no minimum)
Shares Outstanding: 7995918
Prior Maxim ATM: 675,679 shares sold July 1–August 13, 2026 for net proceeds ~$2.8 million after ~$0.1 million commissions; facility fully utilized and terminated
Shelf Capacity: $125,000,000 (Form S-3 shelf)
Series DOffering: $30 million raised Feb 3, 2026; net proceeds ~$7.6 million after ~$22.3 million redemption/refinancing payment; $15.0 million principal 2026 Note issued
Sales Agent Commission: 3.0% of gross sales price
Non Affiliate Float Value: $36,971,233 (6,060,858 shares at $6.10 on July 15, 2026)
Prior12 Month I.B.6 Sales: $2,880,000
Six Month Stock Price Range: $3.85 low to $10.98 high (Mar 4 – Sep 3, 2026)
Estimated Offering Expenses: $100,000 (excluding commissions and A.G.P. reimbursements)
Immediate Dilution Per Share: $1.55 to new investors at assumed $5.09
Net Tangible Book Value Actual: $19.3 million ($3.08/share) as of June 30, 2026
Agent Expense Reimbursement Caps: $65,000 at execution; $7,500 per calendar quarter; $12,500 per program refresh
Shares Outstanding Post Offering: up to 9,842,676 (inclusive of ~1.0 million unvested restricted shares)
Net Tangible Book Value Pro Forma Adjusted: $31.1 million ($3.54/share) after full offering

Price after filing

1 day: -5.5%7 days: -13.3%30 days: -40.5%

Close on the filing date to close N calendar days later (from $4.52). Historical, not a forecast.

AI analysis

Red flags7 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.